CJC-1295 / Ipa 10mg
A highly advanced bipartite peptide formulation combining a Growth Hormone Releasing Hormone analogue with a selective Growth Hormone Secretagogue. This precise 1:1 ratio is engineered to maximize pulsatile somatotropic signaling.
This blended formulation represents the pinnacle of somatotropic peptide research. By pairing CJC-1295 (a GHRH analogue) with Ipamorelin (a selective GHRP), researchers can observe a synergistic amplification of natural pulsatile release. Ipamorelin initiates a robust signal via the ghrelin receptor, while CJC-1295 exponentially amplifies the strength of that pulse without causing unwanted spikes in cortisol or prolactin levels.
Receptor Amplification
CJC-1295 acts directly on the anterior pituitary, extending the half-life of natural releasing hormones and maximizing the total volume of the secretory pulse.
Selective Initiation
Ipamorelin binds to the ghrelin receptor to trigger an immediate, highly selective somatotropic response, completely avoiding the lipogenic side effects of natural ghrelin.
The 1:1 formulation relies on two distinct structural models. CJC-1295 is a tetrasubstituted 29-amino acid peptide modified for enhanced enzymatic stability. Ipamorelin is a synthetic pentapeptide engineered for extreme selectivity. Together, they create an optimal environment for investigating shifts in downstream IGF-1 production.
- Base Origin: GHRH and Ghrelin Analogues
- Primary Action: Synergistic Somatotropic Release
- Cortisol/Prolactin: Zero Documented Elevation
- Cellular Target: Pituitary Somatotrophs
- Downstream Effect: Enhanced Hepatic IGF-1 output
In preclinical models, the CJC-1295 and Ipamorelin complex is extensively investigated for its profound impact on Cellular Hypertrophy and Lipid Mobilization. Researchers routinely monitor circulating IGF-1 levels to determine the true volumetric efficiency of this dual-pathway activation.
Investigating accelerated recovery rates in skeletal muscle and connective tissue following induced mechanical stress.
Analysis of increased basal metabolic rates and the preferential utilization of stored lipids for systemic energy expenditure.
Supplied lyophilised for maximum sequence integrity during logistics.
- Dry Storage: -20°C for >12 months; 2-8°C for <6 months.
- Liquid Stability: Must be refrigerated (2-8°C) once reconstituted.
- Solubility: Water (1mg/ml) or sterile physiological saline.
Strict adherence to laboratory SOPs is required to maintain the stability of both sequences in solution.
- Solvent: Sterile Bacteriostatic Water or PBS.
- Technique: Slow sidewall induction; do not agitate the puck.
- Unit Sizes: 10mg precision research configurations (5mg + 5mg).
WARNING: This compound is a chemical reagent supplied exclusively for in-vitro and in-vivo laboratory research. It is NOT a drug, medication, or food supplement. Strictly prohibited for human or veterinary administration. Lawful handling is the sole responsibility of the professional user. HRS Distribution assumes no liability for applications outside of laboratory scientific research.
Reviews
There are no reviews yet.